Glenn C. Federe

TL;DR: A selective inhibitor of the kinetoplastid proteasome (GNF6702) with unprecedented in vivo efficacy, which cleared parasites from mice in all three models of infection, underscores the possibility of developing a single class of drugs for these neglected diseases.

TL;DR: It is shown here that whole-genome analysis of the parasite can be achieved directly from ex vivo-isolated parasites, without the need for in vitro propagation, and provides a data set for comparative analysis with important potential for identifying markers for global parasite diversity and drug resistance mapping studies.

TL;DR: An attenuated Mycobacterium bovisRD1 deletion (DeltaRD1) mutant of the Ravenel strain was constructed, characterized, and sequenced and may prove useful for bovine TB vaccine programs, particularly if additional mutations are included to improve safety and immunogenicity.

TL;DR: Guide Swap permits genome-scale pooled CRISPR–Cas9 screening in human primary cells by exploiting the unexpected finding that editing by lentivirally delivered, targeted guide RNAs (gRNAs) occurs efficiently when Cas9 is introduced in complex with nontargeting gRNA.

TL;DR: E efficacy of the novel nonbile acid FXR agonist tropifexor (LJN452) in two distinct preclinical models of NASH was superior to that of OCA at 25 mg/kg in the liver in both NASH models.